SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy

JCI insight

Volumn 3, Issue 15, 2018, Pages

  Cassis, Paola ^a   Locatelli, Monica ^a   Cerullo, Domenico ^a   Corna, Daniela ^a   Buelli, Simona ^a   Zanchi, Cristina ^a   Villa, Sebastian ^a   Morigi, Marina ^a   Remuzzi, Giuseppe ^a,b,c   Benigni, Ariela ^a   Zoja, Carlamaria ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Unit of Nephrology and Dialysis   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Chronic kidney disease; Nephrology; Protein traffic

Indexed keywords

2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; BOVINE SERUM ALBUMIN; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SLC5A2 PROTEIN, MOUSE; SMALL INTERFERING RNA; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL; CELL LINE; CHRONIC KIDNEY FAILURE; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METABOLISM; MOUSE; PATHOLOGY; PHARMACOLOGY; PODOCYTE; PROTEINURIA;

ANIMALS; BENZHYDRYL COMPOUNDS; CELL LINE; DISEASE MODELS, ANIMAL; GLUCOSIDES; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MICE; PODOCYTES; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RNA, SMALL INTERFERING; SERUM ALBUMIN, BOVINE; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85060912931     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.98720     Document Type: Article

References (0)